Skip to main content
Premium Trial:

Request an Annual Quote

U of Cincinnati Lands $22.7M from NCRR

NEW YORK (GenomeWeb News) – The University of Cincinnati will use $22.7 million from the National Institutes of Health to start a translational research center that will partner with hospitals in the region to delve into a variety of biomedical science areas including studies that involve proteomics, gene transfer, bioinformatics, imaging, and other applications.

The National Center for Research Resources grant will be spread over five years, and will fund a Center for Clinical and Translational Science and Training (CCTST), which will be a partner in the 39-member NIH-funded Clinical Translational Science Award Consortium.

The center will support the Cincinnati Children's Hospital Medical Center and will collaborate with the Cincinnati Veterans Affairs Medical Center. It also will focus on coordinating and planning the overall direction of the university's research infrastructure and training opportunities, serving needs of researchers, and fostering career development.

"As part of this national clinical and translational research network, the University of Cincinnati will focus on both pediatric and adult diseases and will increase the breadth of consortium activity throughout the Midwest, bringing research advances into the communities it serves," NCRR Director Barbara Alving said in a statement.

The CTSA consortium began in 2006 and when it is fully implemented in 2012 it will connect approximately 60 centers and have an annual budget of around $500 million.

NCRR said in a release that it plans to award more consortium grants this year and will continue taking application for grants it will award in 2010. More information on the CTSA is available at NCRR's website.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more